Document Detail


Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy.
MedLine Citation:
PMID:  16690338     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Both growth hormone (GH) and insulin-like growth factor I (IGF-I) are involved in heart development and in maintenance of cardiac structure and performance. Cardiovascular disease has been reported to reduce life expectancy in both GH deficiency (GHD) and GH excess. Patients with GHD suffer from a cluster of abnormalities associated with increased cardiovascular risk, including abnormal body composition, unfavorable lipid profile, increased fibrinogen and C-reactive protein levels, insulin resistance, early atherosclerosis and endothelial dysfunction, and impaired left ventricular (LV) performance (i.e., reduced diastolic filling and impaired response to peak exercise). Long-term GH replacement therapy reverses most of these abnormalities. More consistently, GH replacement reduces body fat and visceral adipose tissue, reduces low-density lipoprotein cholesterol and triglyceride levels, and improves endothelial function. GH replacement also reduces intima media thickness at major arteries and improves LV performance, but these results have been observed only in small series of patients treated on a short-term basis. This review discusses the roles of GHD and GH replacement therapy in the development of cardiovascular disease.
Authors:
Annamaria Colao; Carolina Di Somma; Maria Cristina Savanelli; Monica De Leo; Gaetano Lombardi
Related Documents :
3907298 - The gemfibrozil study.
12052268 - Early use of statins in acute coronary syndromes.
10918868 - Improved coronary risk assessment with electron beam computed tomography in an asymptom...
15721028 - Endothelium-ameliorating effects of statin therapy and coenzyme q10 reductions in chron...
11875588 - Detection of coronary microvascular disease by means of cardiac scintigraphy.
9391718 - Increased soluble p-selectin following myocardial infarction: a new marker for the prog...
Publication Detail:
Type:  Journal Article; Review     Date:  2006-05-11
Journal Detail:
Title:  Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society     Volume:  16 Suppl A     ISSN:  1096-6374     ISO Abbreviation:  Growth Horm. IGF Res.     Publication Date:  2006 Jul 
Date Detail:
Created Date:  2006-06-26     Completed Date:  2006-12-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9814320     Medline TA:  Growth Horm IGF Res     Country:  Scotland    
Other Details:
Languages:  eng     Pagination:  S41-8     Citation Subset:  IM    
Affiliation:
Department of Molecular and Clinical Endocrinology and Oncology, University Federico II of Naples, Via S. Pansini 5, 80123 Naples, Italy. colao@unina.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Cardiovascular Diseases / diagnosis,  etiology*
Dwarfism, Pituitary / complications*
Growth Hormone / adverse effects*,  therapeutic use*
Hormone Replacement Therapy / adverse effects*
Humans
Chemical
Reg. No./Substance:
9002-72-6/Growth Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of nitrogen dioxide on the EPR property of lithium octa-n-butoxy 2,3-naphthalocyanine (LiNc-B...
Next Document:  Endocrinology--the way we were: a personal history of somatomedin.